New And Special Drugs
-

Redemplo (Plozasiran) – FCS | HongKong DengYue Medicine
-

Yizekang (Izalontamab Brengitecan) – NPC/ESCC | HongKong DengYue Medicine
-

Qiyoukang (Gumokimab) – Plaque Psoriasis | HongKong DengYue Medicine
-

Lukeda (Rocbrutinib) – MCL | HongKong DengYue Medicine
-

Epkinly (Epcoritamab) – Follicular Lymphoma | HongKong DengYue Medicine
-

Blenrep (Belantamab Mafodotin) – Multiple Myeloma | HongKong DengYue Medicine
-

Hyrnuo (Sevabertinib) – NSCLC | HongKong DengYue Medicine
-

Foundayo(Orforglipron) – Obesity/Overweight | HongKong DengYue Medicine
What Can We Offer You?

Generic drugs
Dedicated to providing high-quality, affordable medicines around the world

Vitamins and Supplements
A balanced diet by addressing different deficiencies with the right dosage

brand name medicines
DengYue Medicine as China Drug Import and Export Wholesaler, fills the gap between quality and quantity by adding some affordability

Fast-moving consumer goods
Stock a full range of products from sanitary napkins to foot care creams for your daily needs

non-prescription drugs
Flagship OTC brand - approved and accepted by global standards

Medical supplies and auxiliary supplies
Explore continually updated supplies, diagnostic equipment and essential tools
News
HongKong DengYue Medicine Wholesaler focus on medical trends and obtain new drug directions.

Ciprocopan Approved in China as the World’s First Once-Daily Oral CFB Inhibitor for PNH
Ciprocopan approved in China as the world’s first once-daily oral Complement Factor B (CFB) inhibitor, bringing a new oral treatment option for patients with paroxysmal

Oveporexton Approved First in China: The First OX2R Agonist Targeting the Underlying Mechanism of Type 1 Narcolepsy
Oveporexton approved first in China, becoming the world’s first approved selective orexin receptor 2 (OX2R) agonist and the first therapy designed to target the underlying

Gene Therapy for Beta Thalassemia: Can CRISPR and Gene Addition Achieve Transfusion Independence?
For patients living with transfusion-dependent beta thalassemia (TDT), lifelong blood transfusions have long been the standard of care. While effective in maintaining hemoglobin levels, this

The First Approved ADC for Esophageal Squamous Cell Carcinoma (ESCC): How Izalontamab Brengitecan Is Transforming Treatment
Izalontamab Brengitecan is the first approved ADC for esophageal squamous cell carcinoma (ESCC) worldwide. It is also the world’s first approved EGFR×HER3 bispecific antibody-drug conjugate

Complete Lung Cancer Drugs List (2026 Update)
Lung cancer remains the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Thanks to advances

Adamgammadex Sodium Approved by NMPA: The World’s Second and China’s First Homegrown Targeted Neuromuscular Block Reversal Agent
On July 1, China’s National Medical Products Administration (NMPA) approved Adamgammadex Sodium Injection for marketing. Adamgammadex sodium approved by NMPA marks a major milestone as

ALK Inhibitors for Lung Cancer: Generational Evolution and Impact on Clinical Practice
Before the advent of targeted therapy, ALK-positive advanced non-small cell lung cancer (NSCLC) typically progressed rapidly, with a high incidence of brain metastases and limited

Octahydroaminoacridine Succinate Approved in China for Alzheimer’s Disease, Marking Progress in Innovative Drug Development
On June 25, 2026, the National Medical Products Administration (NMPA) announced Octahydroaminoacridine Succinate approved in China for mild to moderate Alzheimer’s disease, marking another milestone
Fast And Safe Delivery
Global Transportation Express
Temperature-controlled Transport
Safe Transportation, GDP Compliant








